Loading
The trial that showed a gentler CAR-T design could treat adult ALL with a fraction of the severe side effects.
FELIX, trial NCT04404660 sponsored by Autolus and published in the New England Journal of Medicine in 2024, showed that a gentler CAR-T design, obecabtagene autoleucel, could treat adult relapsed or refractory B-cell acute lymphoblastic leukaemia with a fraction of the severe side effects of earlier products. Of 153 enrolled, 127 were infused; the overall remission rate was 77 percent with complete remission in 55 percent, severe cytokine release syndrome occurred in under three percent, and about forty percent were event-free at two years, most without transplant, leading to FDA approval on 8 November 2024 without a REMS programme. OnCo links it to acute lymphoblastic leukaemia, CAR-T, CD19 as a target and obecabtagene autoleucel, and the UCL predecessor ALLCAR19 showed the same profile. Whether the fast-off-rate design generalises to other CAR-T targets is the open question.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares CD19, CAR-T cell therapy, Acute lymphoblastic leukaemia.
Shares CD19, CAR-T cell therapy, Acute lymphoblastic leukaemia.
Shares CD19, CAR-T cell therapy, Acute lymphoblastic leukaemia.
Shares CD19, CAR-T cell therapy, Acute lymphoblastic leukaemia.
Shares CD19, CAR-T cell therapy, Acute lymphoblastic leukaemia.
Shares Relapsed and refractory acute lymphoblastic leukaemia in children, CAR-T cell therapy, Acute lymphoblastic leukaemia.
Shares CD19, CAR-T cell therapy, Acute lymphoblastic leukaemia.
Shares CD19, Acute lymphoblastic leukaemia.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/